Under the CE mark, Kytogen Defend is indicated for superficial tissue filling and for improving skin aspect — such as roughness — and epidermal hydration on the face and décolleté in adults with dehydrated skin.

The material is a highly purified carboxymethyl chitosan developed using patented technology from Belgium-based KiOmed Pharma. Unlike conventional chitosan — extracted from the shells of shrimp and crab — it is derived from the edible white mushroom Agaricus bisporus, making it non-animal in origin and avoiding the shellfish-derived source used in conventional chitosan.

Chitosan itself is a renewable polysaccharide with a long history in biomedicine, used in applications ranging from wound dressings to surgical materials. Sinclair Aesthetics says the material’s water-binding properties are designed to improve the appearance of skin quality and address the look of roughness and dryness.

As part of a global development programme, a pivotal clinical investigation in China completed enrolment of 500 participants in January 2026 in support of future registration there.

The launch enters what is widely regarded as one of medical aesthetics’ fastest-growing areas. Injectable “skin quality” — the skin-booster category — has become a significant growth driver as consumers shift toward natural-looking ageing and longer-term skin maintenance.

Kytogen Defend adds further depth to Sinclair Aesthetics’ portfolio, which spans injectables, energy-based devices, toxins and active skincare. Data presented at AMWC indicate that 59% of consumers favour structured combination-treatment approaches, reflecting the broader shift towards multimodal treatment planning. It complements integrated solutions across facial contouring, volume restoration, wrinkle correction and skin-quality improvement.